Edinburgh Research Explorer

Bystander suppression of experimental arthritis by nasal administration of a heat shock protein peptide

Research output: Contribution to journalArticle

  • Evelien Zonneveld-Huijssoon
  • Sarah T A Roord
  • Wilco de Jager
  • Mark Klein
  • Salvatore Albani
  • Stephen M Anderton
  • Wietse Kuis
  • Femke van Wijk
  • Berent J Prakken

Related Edinburgh Organisations

Original languageEnglish
Pages (from-to)2199-206
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume70
Issue number12
DOIs
Publication statusPublished - 2011

Abstract

Mucosal immune therapy with disease-inducing antigens is an effective way to prevent experimental arthritis, but in humans these antigens are unknown. In juvenile idiopathic arthritis, however, T cell recognition of a so-called bystander antigen, heat shock protein 60 (HSP60), is associated with a good prognosis. Recently epitopes derived from HSP60, a microbial peptide (p1) and its self-homologue (p2) were reported to induce tolerogenic T cell responses in vitro in patients with arthritis. A study was undertaken to determine whether mucosal administration of these bystander epitopes can be similarly effective in suppressing arthritis.

ID: 3572990